Biological Dynamics Collaborates on Clinical Utility Studies to Examine Impact of Its Early Pancreatic Cancer Detection Assay

On November 22, 2022, Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics. Earlier PDAC detection has the potential to improve the survival and quality of lifeĀ for high-risk patients. However, there is a need to understand physician adoption to enhance clinical decisions affecting treatment, patient outcomes, and the use of finite healthcare resources. Therefore, Biological Dynamics will help conduct independent studies on how providers will use its early PDAC detection assay and how the test performance and cost may impact downstream patient care and curative interventions that payors review for reimbursement coverage decisions.

Login Or Register To Read Full Story